Company to be based in Houston with first round funding of $60 million
MD Anderson News Release 08/26/2015
Immatics Biotechnologies GmbH (Immatics) and The University of Texas MD Anderson Cancer Center announced today the launch of Immatics US, Inc., a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types.
Immatics believes that...
MD Anderson News Release 08/26/2015
The University of Texas MD Anderson Cancer Center has appointed former U.S. Public Health Service...
MD Anderson News Release 08/26/2015
Runners and walkers will soon hit the streets for the eighth annual AIM for the CURE Melanoma...
Even despite prognostic factors and co-morbidities associated with poorer outcomes
MD Anderson News Release 08/23/2015
In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. According...
MD Anderson News Release 08/20/2015
With the approval of The University of Texas System Board of Regents today, The University of Texas...
MD Anderson News Release 08/20/2015
The University of Texas Medical Branch at Galveston and The University of Texas MD Anderson Cancer...
Regulation of tumor ‘microenvironment’ may offer alternate approach for treatment
MD Anderson News Release 08/17/2015
Clinical trials to evaluate Merck’s KEYTRUDA® (pembrolizumab) in combination with other medicines and treatments across multiple tumor types...
Ray and the Sunbeatables™ debut through CATCH; arise from MD Anderson research
MD Anderson News Release 08/12/2015
Five...
Dr. Lewis is internationally recognized for her expertise in pelvic sarcoma surgery and substantial contributions in shaping orthopaedic education...
MD Anderson News Release 08/10/2015
A protein called CSN6 has been found to be correlated with poor survival among patients...
MD Anderson researchers recommend hypofractionated treatment as a starting point for treatment discussion between patients, physicians...
Study shows that cell plasticity program resulting from kidney damage can be targeted to reverse disease and fibrosis.
MD Anderson...
The enzyme fumarase key to reversing genetic damage leading to cancer and therapy resistance
MD Anderson News Release 08/03/2015<...